Carole Nuechterlein
Head of Roche Venture Fund @ Roche Venture Fund
Basel, Switzerland
Carole Nuechterlein is a Series A investor at Roche Venture Fund in Basel focused on Biotechnology and Medical. Carole L. Nuechterlein serves as a Head at Roche Venture Fund. She attended University of Michigan.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Carole Nuechterlein invests in
Stages Carole Nuechterlein invests in
Countries Carole Nuechterlein invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (64%)
- Medical 4 (36%)
- Health Care 3 (27%)
- Therapeutics 3 (27%)
- Life Science 2 (18%)
Stage
- Series A 4 (36%)
- Series B 3 (27%)
- Seed 1 (9%)
- Series C 1 (9%)
- Series D 1 (9%)
Country
- United States 5 (45%)
- Italy 1 (9%)
- Spain 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Splice Bio
|
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M / Series B / Jun 11, 2025 | |
Enthera
|
Enthera S.r.l. is a new Italian biotech start-up which mission is to find new therapeutic approaches to treat diabetes and related gastrointestinal complication (enteropathy), as well as other intestinal disorders sharing the same biological pathway. Its name comes from the crasis of the terms entero (referring to the intestine) and therapy.Enthera was founded by BiovelocITA in October 2016 in collaboration with the scientists: Prof. Paolo Fiorina and Dr. Francesca D’Addio. | $8.5M / Series A / Jan 28, 2021 | |
Arch Oncology
|
Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses. | $86M / Series A / Aug 16, 2016 | |
Second Genome
|
Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners acrossgovernment, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases. | $51M / Series B / Apr 20, 2016 | |
AveXis
|
AveXis , doing business as Novartis Gene Therapies, Inc., is a biotechnology company that specializes in the development and commercialization of gene therapies for patients and families affected by rare and life-threatening neurological genetic diseases.AveXis was acquired by Novartis on May 14, 2018. In 2020, the company was renamed NovartisGene Therapies. | $65M / Series D / Sep 08, 2015 | |
Lysosomal Therapeutics
|
Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish aunique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. | $20M / Series A / Feb 03, 2015 | |
|
AveXis
|
AveXis , doing business as Novartis Gene Therapies, Inc., is a biotechnology company that specializes in the development and commercialization of gene therapies for patients and families affected by rare and life-threatening neurological genetic diseases.AveXis was acquired by Novartis on May 14, 2018. In 2020, the company was renamed NovartisGene Therapies. | $10M / Series C / Jan 09, 2015 | |
|
Lysosomal Therapeutics
|
Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish aunique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. | $4.8M / Seed / May 12, 2014 | |
Alios BioPharma
|
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platformtechnologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS). | $41M / Series B / Apr 07, 2014 | |
|
Alios BioPharma
|
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platformtechnologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS). | $24M / Series A / Jun 11, 2009 | |
| See all 11 investments → | |||
Co-Investors
About Roche Venture Fund
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Roche Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Carole Nuechterlein
Head of Roche Venture Fund
|
|||
Monique Schiersing
Investment Director
|
|||
Simon Greenwood
Investment Director
|
|||
Simon Meier
Investment Director
|
|||
Nisha Marathe
Investment Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Carole Nuechterlein invest in?
Carole Nuechterlein invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Carole Nuechterlein?
Public channels for Carole Nuechterlein include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Carole Nuechterlein last invest?
The most recent investment recorded for Carole Nuechterlein closed in Jun 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
